EcoDrugPlus

Transient Receptor Potential Cation Channel, Subfamily A, Member 1a

Ensembl ID : ENSIPUG00000001556
Gene Symbol: TRPA1A
3 Cross references
155 Possible Orthologues:

Transient Receptor Potential Cation Channel, Subfamily A, Member 1b

Ensembl ID : ENSIPUG00000008632
Gene Symbol: TRPA1B
3 Cross references
200 Possible Orthologues:

Transmembrane O-Methyltransferase Homolog

Ensembl ID : ENSIPUG00000009629
Gene Symbol: LOC108268575
3 Cross references
177 Possible Orthologues:

Transthyretin (Prealbumin, Amyloidosis Type I)

Ensembl ID : ENSIPUG00000014900
Gene Symbol: TTR
3 Cross references
178 Possible Orthologues:

Tryptophan Hydroxylase 1 (Tryptophan 5-Monooxygenase) A

Ensembl ID : ENSIPUG00000010464
Gene Symbol: TPH1A
3 Cross references
213 Possible Orthologues:

Tryptophan Hydroxylase 1b

Ensembl ID : ENSIPUG00000018783
Gene Symbol: TPH1B
4 Cross references
176 Possible Orthologues:

Ttk Protein Kinase

Ensembl ID : ENSIPUG00000020423
Gene Symbol: TTK
3 Cross references
204 Possible Orthologues:

Tubulin Alpha-1a Chain-Like

Ensembl ID : ENSIPUG00000022256
Gene Symbol: LOC108275942
3 Cross references
183 Possible Orthologues:

Tubulin Beta Chain

Ensembl ID : ENSIPUG00000018644
Gene Symbol: LOC108261046
3 Cross references
15 Possible Orthologues:

Tubulin Beta Chain

Ensembl ID : ENSIPUG00000024831
Gene Symbol: LOC108277165
3 Cross references
15 Possible Orthologues:

Tubulin Beta Chain-Like

Ensembl ID : ENSIPUG00000024891
Gene Symbol: LOC108278890
3 Cross references
15 Possible Orthologues:

Tubulin Beta-4b Chain

Ensembl ID : ENSIPUG00000013391
Gene Symbol: LOC108258863
3 Cross references
15 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).